- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01648153
Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM (T2DM)
A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects With T2DM.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The study will be a randomised, single-blind (sponsor-unblinded), placebo-controlled, study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of repeat intravenous infusions (2 doses 4-weeks apart) of GSK1070806 in obese patients with T2DM. The primary objective of the study will be to assess improvements in fasting and postprandial glucose control. This will be a parallel-group study in 30 obese subjects with T2DM who are poorly controlled on metformin monotherapy (HbA1C>7% but <9.5%), and who have levels of microalbuminuria indicative of progressive kidney disease i.e. 30-300mg/L albumin in urine or ACR ≥3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤30mg/mmol. There will be three treatment groups comprising two active and one placebo arm with 10 subjects per dose group. The study contains a broad range of biomarker assessments, the purpose of which is to evaluate the mechanistic basis by which GSK1070806 exerts its therapeutic benefit in subjects with T2DM.
Subjects will be randomised into one of the three treatment groups where they will receive two intravenous infusions of GSK1070806 or placebo twenty-eight days apart. A MMT challenge will be conducted on Day 1, Day 29, Day 57 and Day 85 for evaluation of the primary endpoints.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
-
Alicante, Spanien, 03004
- GSK Investigational Site
-
Alzira/Valencia, Spanien, 46600
- GSK Investigational Site
-
Granada, Spanien, 18012
- GSK Investigational Site
-
La Roca del Valles (Barcelona), Spanien, 08430
- GSK Investigational Site
-
Lleida, Spanien, 25198
- GSK Investigational Site
-
Madrid, Spanien, 28046
- GSK Investigational Site
-
Madrid, Spanien, 28034
- GSK Investigational Site
-
Malaga, Spanien, 29010
- GSK Investigational Site
-
Málaga, Spanien, 29010
- GSK Investigational Site
-
Petrer, Alicante, Spanien, 03610
- GSK Investigational Site
-
Santander, Spanien, 39008
- GSK Investigational Site
-
-
-
-
-
Cambridge, Vereinigtes Königreich, CB2 2GG
- GSK Investigational Site
-
Dundee, Vereinigtes Königreich, DD1 9SY
- GSK Investigational Site
-
-
Warwickshire
-
Birmingham, Warwickshire, Vereinigtes Königreich, B15 2TT
- GSK Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- A diagnosis of T2DM as determined by a responsible physician based on a medical evaluation including medical history, physical examination, and laboratory tests, with onset at least 6 months prior to Screening.
- Male or female between 18 and 70 years of age inclusive, at the time of signing the informed consent.
- HbA1c levels ≥ 7.0 % and ≤ 9.5%; at Screening.
- On a stable dose of monotherapy with metformin for three months prior to screening, and at a total daily dose greater than or equal to 1000 mg for at least 2 months prior to dosing.
- Fasting plasma glucose level < 13.3 mmol/L (240 mg/dL) at screening.
- Obese with BMI ≥ 30 kg/m2, and < 40 kg/m2.
- Presence of microalbuminuria: 30-300mg/L albumin in urine or Albumin Creatinine Ratio (ACR) ≥ 3.5 mg/mmol (female) or ≥2.5 mg/mmol (male) and ≤ 30 mg/mmol (female and male)..
- The subject is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
A female subject is eligible to participate if she is of:
- Non-childbearing potential
- Child-bearing potential and agrees to use an acceptable form of contraception.
- Male subjects must agree to use one of the contraception methods listed
- ALT < 2xULN; alkaline phosphatase and bilirubin ≤ 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Single or Average QTc, QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.
Exclusion Criteria:
- Current evidence, or history within the last 7 days, of an influenza-like illness as defined by fever (>38°C) and two or more of the following symptoms: cough, sore throat, runny nose, sneezing, limb / joint pain, headache, vomiting / diarrhoea in the absence of a known cause, other than influenza.
- Use of anti-inflammatory drugs including corticosteroids, chronic maintenance therapy with NSAIDs, anti-Tumor Necrosis Factor (anti-TNF) or anti-Interleukin-1 (anti-IL1) within 60 days prior to dosing.
- Current evidence of ongoing or acute infection, history of repeated, chronic or opportunistic infections (e.g. recurrent folliculitis, other cutaneous infections or repeated pneumonia) or history of a serious bacterial infection within 6 months of randomisation.
- History of malignancy or significant cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions.
- History chronic granulomatous infections, such as of Mycobacterium tuberculosis or any other previous Mycobacterium infection.
- Creatinine clearance less than 60ml/min
- Screens positive of Hepatitis B surface antigen, Hepatitis C antibody or Human Immunodeficiency Virus (HIV)
- History of a severe allergic reaction, anaphylaxis or immunodeficiency.
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A positive pre-study drug/alcohol screen.
- History of regular alcohol consumption within 6 months of the study
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication.
- History of sensitivity to any of the study medications, or components thereof
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
- Pregnant females as determined by positive serum or urine hCG test at screening.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- Subject has received a live attenuated vaccine(s) within 30 days of randomisation or will require vaccination with a live attenuated vaccine prior to the end of the study.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: GSK1070806 0.25mg/kg
TwoIV administrations of 0.25mg/kg GSK1070806 4weeks apart
|
To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
|
Aktiver Komparator: GSK1070806 5mg/kg
Two IV administrations of 5mg/kg of GSK1070806 4 weeks apart
|
To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
|
Placebo-Komparator: Placebo (Saline)
Two IV administrations of saline 4 weeks apart
|
To compare the efficacy and biomarker changes between placebo and active groups
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Change from baseline in fasting plasma glucose and weighted mean glucose AUC (0-4hrs) post-Mixed Meal Test (MMT)
Zeitfenster: Up to 85 days after the first does
|
To evaluate the efficacy of two repeat intravenous dose administrations of GSK1070806 in subjects with T2DM
|
Up to 85 days after the first does
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Safety and tolerability parameters include: adverse events, clinical laboratory tests, electrocardiograms (ECGs), and vital signs
Zeitfenster: Up to 210 days after the first dose
|
To evaluate the safety and tolerability of two repeat intravenous dose administrations of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Change from baseline in % HbA1c, fasting blood insulin, and C-peptide levels; change from baseline in weighted mean insulin, and C-peptide levels [AUC (0-4hrs)] post-MMT and derived measures of insulin sensitive
Zeitfenster: Up to 85 days after the first dose
|
To evaluate the effect of two repeat intravenous dose administrations of GSK1070806 on additional markers of efficacy, in obese subjects with T2DM
|
Up to 85 days after the first dose
|
AUC(0-τ)
Zeitfenster: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Serum levels of free IL-18 and drug bound IL 18
Zeitfenster: Up to 210 days after the first dose
|
To investigate the effect of repeat intravenous doses of GSK1070806 on free and drug bound IL 18 levels (if measurable) in obese subjects with T2DM.
|
Up to 210 days after the first dose
|
Change from baseline in serum and/or plasma levels of biomarkers of inflammation (e.g. hs-CRP, and IL-6) and metabolic disease (e.g. adiponectin, fructosamine, total cholesterol, high-density lipoprotein (HDL)/low-density lipoprotein (LDL), triglycerides
Zeitfenster: Up to 85 days after the first dose
|
To explore the pharmacodynamic (PD) effect of repeat intravenous doses of GSK1070806 on biomarkers of inflammation and metabolic disease
|
Up to 85 days after the first dose
|
Change from baseline in waist circumference and BMI
Zeitfenster: Up to 85 days after the first dose
|
To investigate the effect of repeat intravenous doses of GSK1070806 on body composition in obese subjects with T2DM
|
Up to 85 days after the first dose
|
Cmax
Zeitfenster: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Tmax
Zeitfenster: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
after the second dose λz
Zeitfenster: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
t1/2
Zeitfenster: Up to 210 days after the first dose
|
To evaluate the plasma PK of repeat intravenous doses of GSK1070806 in obese subjects with T2DM
|
Up to 210 days after the first dose
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
- 116378
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Studiendaten/Dokumente
-
Datensatzspezifikation
Informationskennung: 116378Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Kommentiertes Fallberichtsformular
Informationskennung: 116378Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Studienprotokoll
Informationskennung: 116378Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistischer Analyseplan
Informationskennung: 116378Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Einzelner Teilnehmerdatensatz
Informationskennung: 116378Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Einwilligungserklärung
Informationskennung: 116378Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinischer Studienbericht
Informationskennung: 116378Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Diabetes Mellitus
-
Medical College of WisconsinMedical University of South CarolinaAbgeschlossenDiabetes Mellitus | Typ 2 Diabetes mellitus | Altersdiabetes mellitus | Nicht insulinabhängiger Diabetes mellitus | Nicht insulinabhängiger Diabetes Mellitus, Typ IIVereinigte Staaten
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AbgeschlossenDiabetes mellitus, Typ 1 | Diabetes Typ 1 | Diabetes Typ1 | Diabetes mellitus Typ 1 | Autoimmundiabetes | Diabetes mellitus, insulinabhängig | Jugenddiabetes | Diabetes, Autoimmun | Insulinabhängiger Diabetes mellitus 1 | Diabetes mellitus, insulinabhängig, 1 | Diabetes mellitus, spröde | Diabetes mellitus... und andere BedingungenVereinigte Staaten
-
Guang NingRekrutierungTyp 2 Diabetes mellitus | Diabetes mellitus Typ1 | Monogenetischer Diabetes | Pankreatogener Diabetes | Medikamenteninduzierter Diabetes mellitus | Andere Formen von Diabetes mellitusChina
-
SanofiAbgeschlossenDiabetes mellitus Typ 1 – Diabetes mellitus Typ 2Ungarn, Russische Föderation, Deutschland, Polen, Japan, Vereinigte Staaten, Finnland
-
Meir Medical CenterAbgeschlossenDiabetes mellitus Typ 2 | Diabetes mellitus, nicht insulinabhängig | Diabetes mellitus, zur oralen hypoglykämischen Behandlung | Diabetes mellitus vom ErwachsenentypIsrael
-
Joslin Diabetes CenterCambridge Medical Technologies, LLCAbgeschlossenTyp 2 Diabetes mellitus | Diabetes mellitus Typ1Vereinigte Staaten
-
Hoffmann-La RocheRoche DiagnosticsAbgeschlossenDiabetes mellitus Typ 2, Diabetes mellitus Typ 1Deutschland
-
Hanmi Pharmaceutical Company LimitedUnbekanntTyp 2 Diabetes mellitus | Diabetes mellitus Typ1Vereinigte Staaten
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAbgeschlossenDiabetes mellitus Typ 1 | Diabetes mellitus, Typ I | Insulinabhängiger Diabetes mellitus 1 | Diabetes mellitus, insulinabhängig, 1 | IDDMVereinigte Staaten, Australien
-
Leiden University Medical CenterAndaluz Health ServiceAbgeschlossenDiabetes Mellitus | Gesundheitsverhalten | Selbstwirksamkeit | Typ 2 Diabetes mellitus | Diabetes mellitus Typ1Niederlande, Spanien
Klinische Studien zur GSK1070806
-
GlaxoSmithKlineAbgeschlossenDermatitis, atopischVereinigte Staaten, Kanada
-
GlaxoSmithKlineRekrutierungDermatitis, atopischKanada, Spanien, China, Vereinigte Staaten, Argentinien, Polen, Korea, Republik von, Panama, Japan, Bulgarien, Tschechien, Frankreich, Deutschland, Griechenland, Italien, Mexiko, Thailand
-
Cambridge University Hospitals NHS Foundation TrustUnbekannt
-
GlaxoSmithKlineAbgeschlossenEntzündliche DarmerkrankungenVereinigtes Königreich
-
GlaxoSmithKlineAbgeschlossenDermatitis, atopischVereinigte Staaten
-
University of BirminghamGlaxoSmithKline; University Hospital BirminghamAbgeschlossenMorbus CrohnVereinigtes Königreich
-
Seoul National University HospitalNoch keine RekrutierungHypotonie | Intraoperative Komplikationen | Neugeborene Hypotonie
-
GlaxoSmithKlineBeendetNierentransplantation (Status Post)Vereinigtes Königreich, Spanien